Suchergebnisse - "Moehler, Markus"

PubPharm (22)

1

Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy : the phase II/III RAMIRIS study (AIO-STO-0415)

enthalten in: BMC cancer | 2023

von Lorenzen, S. | Schwarz, A. | Pauligk, C. | +12

2

Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer : subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306

enthalten in: European radiology | 2023

von Hofmann, F. | Heinemann, V. | D'Anastasi, M. | +15

3

Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)

enthalten in: International journal of cancer | 2022

von Liu, L. | Erickson, N. | Ricard, I. | +20

ErratumIn: Int J Cancer. 2022 May 1;150(9):E5. - PMID 35353388

4

Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3)

enthalten in: International journal of cancer | 2021

von Stahler, A. | Heinemann, V. | Holch, J. | +17

5

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer : final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

enthalten in: British journal of cancer | 2021

von Heinemann, V. | von Weikersthal, L. | Decker, T. | +16

6

Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer : results from the FIRE-3 (AIO KRK-0306) study

enthalten in: Anti-cancer drugs | 2020

von Schulz, C. | Heinemann, V. | Heinrich, K. | +12

7

Chemotherapy for advanced gastric cancer

enthalten in: The Cochrane database of systematic reviews | 2017

von Wagner, A. | Syn, N. | Moehler, M. | +5

UpdateOf: Cochrane Database Syst Rev. 2010 Mar 17;(3):CD004064. - PMID 20238327

8

Dermatux : phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care

enthalten in: Journal of cancer research and clinical oncology | 2017

von Schimanski, C. | Staib, F. | Göhler, T. | +18

9

Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306)

enthalten in: International journal of cancer | 2017

von Modest, D. | Stintzing, S. | Fischer von Weikersthal, L. | +18

10

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3) : a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

enthalten in: The Lancet. Oncology | 2016

von Stintzing, S. | Modest, D. | Rossius, L. | +21

ErratumIn: Lancet Oncol. 2016 Oct;17 (10 ):e420. - PMID 27592806